Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

@article{Campbell2014CharacterizationOL,
  title={Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.},
  author={Robert M. Campbell and Bryan D. Anderson and Nathan A. Brooks and Harold B. Brooks and Edward Michael Chan and Alfonso de Dios and Raymond Gilmour and Jeremy R. Graff and Enrique Jambrina and Mary M. Mader and D J Mccann and Songqing Na and Stephen H. Parsons and Susan E. Pratt and C -Y.T. Shih and Louis F. Stancato and James J. Starling and Courtney Tate and J A M{\'e}rida Velasco and Yong Wang and Xiang S. Ye},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 2},
  pages={364-74}
}
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and regulates the production of cytokines in the tumor microenvironment, such as TNF-α, interleukin-1β (IL-1β), IL-6, and CXCL8 (IL-8). p38α MAPK is highly expressed in human cancers and may play a role in tumor growth, invasion, metastasis, and drug resistance… CONTINUE READING
Highly Cited
This paper has 37 citations. REVIEW CITATIONS
24 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Constitutively active inflammasome in human melanoma cells mediating Campbell et al. Mol Cancer Ther

  • M Okamoto, W Liu, Y Luo, A Tanaka, X Cai, DA Norris
  • Molecular Cancer Therapeutics OF10 on April
  • 2014

Similar Papers

Loading similar papers…